Sanofi announces that Brussels has extended the marketing authorization (MA) for its Dupixent in the EU, making it the first and only targeted drug specifically indicated for the treatment of eosinophilic esophagitis in Europe and the United States.

The marketing authorization for this chronic inflammatory disease covers adults and adolescents aged 12 and over, weighing at least 40 kg and inadequately controlled by, intolerant of or not recommended for conventional drugs.

Approximately 60% of patients aged 12 and over treated with Dupixent 300 mg once weekly in a pivotal trial showed histological remission, as well as a significant improvement in their ability to swallow, compared to placebo.

Copyright (c) 2023 CercleFinance.com. All rights reserved.